300657-03-8
中文名稱
[2'-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]-ACETIC ACID
英文名稱
2''-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETIC ACID
CAS
300657-03-8
分子式
C31H26N2O3
分子量
474.55
MOL 文件
300657-03-8.mol
更新日期
2025/01/14 17:14:46
300657-03-8 結(jié)構(gòu)式
基本信息
中文別名
化合物BMS-3094032-(5-乙基-3,4-二苯基-吡唑-1-基)-聯(lián)苯-3-基氧基]乙酸
2'-(5-乙基-3,4-二苯基-吡唑-1-基)-雙苯基-3-氧基]乙酸
2-[[2'-(5-乙基-3,4-二苯基-1H-吡唑-1-基)[1,1'-聯(lián)苯]-3-基]氧基]乙酸
英文別名
CS-495BMS309403
BMS 309403
BMS309403
BMS-309403 >=98% (HPLC)
3-[2-(5-ETHYL-3,4-DIPHENYLPYRAZOL-1-YL)PHENYL]PHENOXYACETIC ACID
2''-(5-ETHYL-3,4-DIPHENYL-PYRAZOL-1-YL)-BIPHENYL-3-YLOXY]ACETIC ACID
2-[3-[2-(5-ethyl-3,4-diphenylpyrazol-1-yl)phenyl]phenoxy]acetic acid
2-[[2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]oxy]- acetic acid
Acetic acid, 2-[[2'-(5-ethyl-3,4-diphenyl-1H-pyrazol-1-yl)[1,1'-biphenyl]-3-yl]oxy]-
物理化學(xué)性質(zhì)
沸點(diǎn)657.5±55.0 °C(Predicted)
密度1.17
儲(chǔ)存條件Sealed in dry,Room Temperature
溶解度可溶于 DMSO（高達(dá)至少 25 mg/ml）。
酸度系數(shù)(pKa)3.15±0.10(Predicted)
形態(tài)白色粉末狀固體。
顏色灰白色或淺黃色
穩(wěn)定性可在-20°下的DMSO中的溶液儲(chǔ)存長(zhǎng)達(dá)1個(gè)月。
BMS309403價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | S6622 | BMS309403 BMS309403 | 300657-03-8 | 5mg | 794.93元 |
| 2024/11/08 | S6622 | BMS309403 | 300657-03-8 | 10mM (1mL in DMSO) | 958.23元 |
| 2024/11/08 | HY-101903 | BMS309403 BMS-309403 | 300657-03-8 | 5mg | 700元 |
常見問(wèn)題列表
生物活性
BMS309403是FABP4小分子抑制劑，Kd值為4 nM，對(duì)FABP4的選擇性比對(duì)FABP5和FABP3高100倍以上。靶點(diǎn)
| Target | Value |
|
FABP4
(Cell-free assay) | 4 nM(Kd) |
體外研究
Treatment with BMS-309403 significantly decreased MCP-1 production from THP-1 macrophages in a dose- and time-dependent manner.
體內(nèi)研究
BMS-309403 sodium (15 mg/kg; chronic treatment; daily for 6 weeks) improves endothelial function, phosphorylated and total eNOS and reduced plasma triglyceride levels but did not affect endothelium-independent relaxations.
| Animal Model: | C57BL/6J mice (ApoE ?/? mice) |
| Dosage: | 15 mg/kg |
| Administration: | Chronic treatment ; daily for 6 weeks |
| Result: | Significantly increased the phosphorylated eNOS (Ser1177) and total eNOS but not the phosphorylated to total eNOS ratio in aortae of 18 weeks old ApoE ?/? mice. |